

## HR 5497

Conditional Approval Act

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Dec 19, 2019

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Dec 20, 2019)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/5497>

### Sponsor

**Name:** Rep. Westerman, Bruce [R-AR-4]

**Party:** Republican • **State:** AR • **Chamber:** House

### Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Burchett, Tim [R-TN-2]	R · TN		Dec 19, 2019
Rep. Gallagher, Mike [R-WI-8]	R · WI		Dec 19, 2019

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Dec 20, 2019

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

Bill	Relationship	Last Action
116 S 3133	Related bill	<b>Dec 19, 2019:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

### Summary (as of Dec 19, 2019)

#### Conditional Approval Act

This bill authorizes the Food and Drug Administration to conditionally approve certain new drugs intended for diseases that are seriously debilitating, life threatening, or chronic, and for which meaningful treatments do not exist. The bill also limits liability related to these conditionally approved drugs.

### Actions Timeline

- **Dec 20, 2019:** Referred to the Subcommittee on Health.
- **Dec 19, 2019:** Introduced in House
- **Dec 19, 2019:** Referred to the House Committee on Energy and Commerce.